Anti-Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984)

Overview

• Product nameAnti-Lamin A + C antibody [131C3] - Nuclear Envelope MarkerSee all Lamin A + C primary antibodies ...
• Description
  Mouse monoclonal [131C3] to Lamin A + C - Nuclear Envelope Marker
• Specificityab8984 reacts with lamins A and C. Lamins do not appear to be universally distributed among different cell and tissue types. ab8984 has been shown to react with HT1080 cells in Western blot. Other cell/tissue types have not been tested. Customer feedback seems to indicate that ab8984 does not detect Lamin A+C in rat brain lysates (please see AbReviews).
• Tested applicationsIP, Flow Cyt, ICC, IHC-Fr, WB, ICC/IF more details
• Species reactivity
  Reacts with: Mouse, Rat, Sheep, Hamster, Cow, Dog, Human, Indian Muntjac
  
• Immunogen

  Purified rat liver lamins.

• EpitopeBetween residues 319-566.
• Positive controlIHC: human colon WB: Human fibroblast, HT1080 cells

Properties

• FormLiquid
• Storage instructionsStore at +4°C short term (1-2 weeks). Aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
• Storage bufferPreservative: 0.09% Sodium Azide
  Constituents: PBS
• Concentration information loading...
• PurityProtein G purified
• Clonality Monoclonal
• Clone number131C3
• MyelomaP3x63-Ag8.653
• IsotypeIgG1
• Light chain typekappa
• Research Areas
  • Signal Transduction
  • Cytoskeleton / ECM
  • Cytoskeleton
  • Intermediate Filaments
  • Class V
  • Lamins

  • Tags & Cell Markers
  • Subcellular Markers
  • Nucleus
  • Nuclear Envelope

Applications

Target

• FunctionLamins are components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane, which is thought to provide a framework for the nuclear envelope and may also interact with chromatin. Lamin A and C are present in equal amounts in the lamina of mammals. Play an important role in nuclear assembly, chromatin organization, nuclear membrane and telomere dynamics.
  Prelamin-A/C can accelerate smooth muscle cell senescence. It acts to disrupt mitosis and induce DNA damage in vascular smooth muscle cells (VSMCs), leading to mitotic failure, genomic instability, and premature senescence.
• Tissue specificityIn the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle celle (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
• Involvement in diseaseDefects in LMNA are the cause of Emery-Dreifuss muscular dystrophy type 2 (EDMD2) [MIM:181350]. A degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.
  Defects in LMNA are the cause of cardiomyopathy dilated type 1A (CMD1A) [MIM:115200]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  Defects in LMNA are the cause of familial partial lipodystrophy type 2 (FPLD2) [MIM:151660]; also known as familial partial lipodystrophy Dunnigan type. A disorder characterized by the loss of subcutaneous adipose tissue in the lower parts of the body (limbs, buttocks, trunk). It is accompanied by an accumulation of adipose tissue in the face and neck causing a double chin, fat neck, or cushingoid appearance. Adipose tissue may also accumulate in the axillae, back, labia majora, and intraabdominal region. Affected patients are insulin-resistant and may develop glucose intolerance and diabetes mellitus after age 20 years, hypertriglyceridemia, and low levels of high density lipoprotein cholesterol.
  Defects in LMNA are the cause of limb-girdle muscular dystrophy type 1B (LGMD1B) [MIM:159001]. LGMD1B is an autosomal dominant degenerative myopathy with age-related atrioventricular cardiac conduction disturbances, dilated cardiomyopathy, and the absence of early contractures. LGMD1B is characterized by slowly progressive skeletal muscle weakness of the hip and shoulder girdles. Muscle biopsy shows mild dystrophic changes.
  Defects in LMNA are the cause of Charcot-Marie-Tooth disease type 2B1 (CMT2B1) [MIM:605588]. CMT2B1 is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. CMT2B1 inheritance is autosomal recessive.
  Defects in LMNA are the cause of Hutchinson-Gilford progeria syndrome (HGPS) [MIM:176670]. HGPS is a rare genetic disorder characterized by features reminiscent of marked premature aging. Note=HGPS is caused by the toxic accumulation of a mutant form of lamin-A/C. This mutant protein, called progerin, acts to deregulate mitosis and DNA damage signaling, leading to premature cell death and senescence. Progerin lacks the conserved ZMPSTE24/FACE1 cleavage site and therefore remains permanently farnesylated. Thus, although it can enter the nucleus and associate with the nuclear envelope, it cannot incorporate normally into the nuclear lamina.
  Defects in LMNA are the cause of cardiomyopathy dilated with hypergonadotropic hypogonadism (CMDHH) [MIM:212112]. A disorder characterized by the association of genital anomalies, hypergonadotropic hypogonadism and dilated cardiomyopathy. Patients can present other variable clinical manifestations including mental retardation, skeletal anomalies, scleroderma-like skin, graying and thinning of hair, osteoporosis. Dilated cardiomyopathy is characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia.
  Defects in LMNA are the cause of mandibuloacral dysplasia with type A lipodystrophy (MADA) [MIM:248370]. A disorder characterized by mandibular and clavicular hypoplasia, acroosteolysis, delayed closure of the cranial suture, progeroide appearance, partial alopecia, soft tissue calcinosis, joint contractures, and partial lipodystrophy with loss of subcutaneous fat from the extremities. Adipose tissue in the face, neck and trunk is normal or increased.
  Defects in LMNA are a cause of lethal tight skin contracture syndrome (LTSCS) [MIM:275210]; also known as restrictive dermopathy (RD). Lethal tight skin contracture syndrome is a rare disorder mainly characterized by intrauterine growth retardation, tight and rigid skin with erosions, prominent superficial vasculature and epidermal hyperkeratosis, facial features (small mouth, small pinched nose and micrognathia), sparse/absent eyelashes and eyebrows, mineralization defects of the skull, thin dysplastic clavicles, pulmonary hypoplasia, multiple joint contractures and an early neonatal lethal course. Liveborn children usually die within the first week of life. The overall prevalence of consanguineous cases suggested an autosomal recessive inheritance.
  Defects in LMNA are the cause of heart-hand syndrome Slovenian type (HHS-Slovenian) [MIM:610140]. Heart-hand syndrome (HHS) is a clinically and genetically heterogeneous disorder characterized by the co-occurrence of a congenital cardiac disease and limb malformations.
  Defects in LMNA are the cause of muscular dystrophy congenital LMNA-related (CMD-LMNA) [MIM:613205]. It is a form of congenital muscular dystrophy. Patients present at birth, or within the first few months of life, with hypotonia, muscle weakness and often with joint contractures.
• Sequence similaritiesBelongs to the intermediate filament family.
• Post-translational
  modificationsIncreased phosphorylation of the lamins occurs before envelope disintegration and probably plays a role in regulating lamin associations.
  Proteolytic cleavage of the C-terminal of 18 residues of prelamin-A/C results in the production of lamin-A/C. The prelamin-A/C maturation pathway includes farnesylation of CAAX motif, ZMPSTE24/FACE1 mediated cleavage of the last three amino acids, methylation of the C-terminal cysteine and endoproteolytic removal of the last 15 C-terminal amino acids. Proteolytic cleavage requires prior farnesylation and methylation, and absence of these blocks cleavage.
  Sumoylation is necessary for the localization to the nuclear envelope.
  Farnesylation of prelamin-A/C facilitates nuclear envelope targeting.
• Cellular localizationNucleus. Nucleus envelope. Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleaveage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.

Target information above from: UniProt accession P02545 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010) .

Information by UniProt
• Database links
  • Entrez Gene: 4000 Human
  • Entrez Gene: 16905 Mouse
  • Entrez Gene: 60374 Rat
  • Omim: 150330 Human
  • SwissProt: P02545 Human
  • SwissProt: P48678 Mouse
  • SwissProt: P48679 Rat
  • Unigene: 594444 Human

  • Unigene: 243014 Mouse
  • Unigene: 471227 Mouse
  • Unigene: 44161 Rat

  see all

• Alternative names
  70 kDa Lamin antibodyCardiomyopathy dilated 1A (autosomal dominant) antibodyCDCD1 antibody

  CDDC antibodyCharcot Marie Tooth Disease Axonal Type 2B1 antibodyCMD1A antibodyCMT2B1 antibodyEMD2 antibodyFPL antibodyFPLD antibodyFPLD2 antibodyHGPS antibodyIDC antibodyLamin A/C antibodyLamin A/C Isoform 1 Precursor antibodyLamin A/C Isoform 2 antibodyLamin A/C Isoform 3 antibodyLamin A/C like 1 antibodyLamin-A/C antibodyLDP1 antibodyLFP antibodyLGMD1B antibodyLimb girdle muscular dystrophy 1B (autosomal dominant) antibodyLMN 1 antibodyLMN A antibodyLMN C antibodyLMN1 antibodyLMNA antibodyLMNA_HUMAN antibodyLMNC antibodyLMNC antibodyNY REN 32 antigen antibodyPrelamin A/C antibodyPRO1 antibodyProgeria 1 (Hutchinson Gilford Type) antibodyRenal carcinoma antigen NY REN 32 antibodyRenal carcinoma antigen NY-REN-32 antibodyRenal carcinoma antigen NYREN32 antibody

  see all

Anti-Lamin A + C antibody [131C3] - Nuclear Envelope Marker images

• 

  Western blot - Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984)
  
  
  Predicted band size : 70 kDa
  
  
  

  A. HT1080 cells + siRNA control sequence

  B. HT1080 cells + siRNA Lamin

  This picture was submitted by Andrea Robertson as part of a review of ab8984

• 

  Immunocytochemistry/ Immunofluorescence - Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984)

  ab8984 at a 1/200 dilution staining Asynchronous and paraformaldehyde-fixed (4%) HeLa cells by immunocytochemistry. The antibody was incubated with the cells overnight and then detected using a Cy3 conjugated Goat Anti-Mouse IgG (H+L) antibody. The image shows faint, but distinct, nuclear membrane staining.

  This image is courtesy of an Abreview by Kirk McManus submitted on 27 February 2006.

  See Abreview

• 

  Western blot - Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984)
  All lanes : Anti-Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984) at 1/1000 dilution
  
  Lane 1 : 10ug HeLa whole cell lysate
  Lane 2 : 50ug HeLa whole cell lysate
  Lane 3 : 100ug HeLa whole cell lysate
  
  Secondary
  HRP conjugated goat anti-mouse antibody
  developed using the ECL technique
  
  Predicted band size : 70 kDa
  Observed band size : 70 kDa
  
  
  Exposure time : 30 seconds

  This image is courtesy of an Abreview submitted by Ms Aarti Jagannath

  See Abreview

• 

  Immunocytochemistry/ Immunofluorescence - Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984)This image is courtesy of an anonymous Abreview

  ab8984 staining dog skeletal muscle tissue cells by ICC/IF.  Cells were fixed in methanol and incubated with ab8984, diluted 1/200, for 12 hours at 4°C.  A FITC conjugated goat anti-mouse antibody, diluted 1/200, was used as the secondary antibody.

  See Abreview

• 

  Western blot - Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984)
  Anti-Lamin A + C antibody [131C3] - Nuclear Envelope Marker (ab8984) at 1/100 dilution + human fibroblast at 15 µl
  developed using the ECL technique
  
  Performed under reducing conditions.
  
  Predicted band size : 70 kDa
  
  
  Lysates were prepared in RIPA buffer on ice for 30 min. They were sonicated 4 times for 5 sec prior to mixing with loading buffer.
• 

  Flow Cytometry-Lamin A + C antibody [131C3] - Nuclear Envelope Marker(ab8984)
  Overlay histogram showing HeLA cells stained with ab8984 (red line). The cells were fixed with 100% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab8984, 1µg/1x10⁶ cells) for 30 min at 22°C. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22°C. Isotype control antibody (black line) was Mouse IgG1 [ICIGG1] (ab91353, 2µg/1x10⁶ cells) used under the same conditions. Acquisition of >5,000 events was performed.